1887
  1. Home
  2. Eurosurveillance
  3. Volume 29, Issue 31, 01/Aug/2024
  4. Article
Surveillance Open Access
Like 0
Download

Abstract

Background

is a leading cause of moderate-to-severe diarrhoea worldwide and diarrhoeal deaths in children in low- and-middle-income countries.

Aim

We investigated trends and characteristics of shigellosis and antimicrobial resistance of in Israel.

Methods

We analysed data generated by the Sentinel Laboratory-Based Surveillance Network for Enteric Pathogens that systematically collects data on detection of at sentinel laboratories, along with the characterisation of the isolates at the National Reference Laboratory. Trends in the shigellosis incidence were assessed using Joinpoint regression and interrupted time-series analyses.

Results

The average incidence of culture-confirmed shigellosis in Israel declined from 114 per 100,000 population (95% confidence interval (CI): 112–115) 1998–2004 to 80 per 100,000 population (95% CI: 79–82) 2005–2011. This rate remained stable 2012–2019, being 18–32 times higher than that reported from the United States or European high-income countries. After decreasing to its lowest values during the COVID-19 pandemic years (19/100,000 in 2020 and 5/100,000 in 2021), the incidence of culture-confirmed shigellosis increased to 39 per 100,000 population in 2022. is the most common serogroup, responsible for a cyclic occurrence of propagated epidemics, and the proportion of has decreased. Simultaneous resistance of to ceftriaxone, ampicillin and sulphamethoxazole-trimethoprim increased from 8.5% (34/402) in 2020 to 92.0% (801/876) in 2022.

Conclusions

These findings reinforce the need for continuous laboratory-based surveillance and inform the primary and secondary prevention strategies for shigellosis in Israel and other endemic high-income countries or communities.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2024.29.31.2400022
2024-08-01
2024-12-12
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2024.29.31.2400022
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/29/31/eurosurv-29-31-2.html?itemId=/content/10.2807/1560-7917.ES.2024.29.31.2400022&mimeType=html&fmt=ahah

References

  1. Troeger C, Blacker BF, Khalil IA, Rao PC, Cao S, Zimsen SRM, et al. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018;18(11):1211-28.  https://doi.org/10.1016/S1473-3099(18)30362-1  PMID: 30243583 
  2. DuPont HL, Levine MM, Hornick RB, Formal SB. Inoculum size in shigellosis and implications for expected mode of transmission. J Infect Dis. 1989;159(6):1126-8.  https://doi.org/10.1093/infdis/159.6.1126  PMID: 2656880 
  3. Mohle-Boetani JC, Stapleton M, Finger R, Bean NH, Poundstone J, Blake PA, et al. Communitywide shigellosis: control of an outbreak and risk factors in child day-care centers. Am J Public Health. 1995;85(6):812-6.  https://doi.org/10.2105/AJPH.85.6.812  PMID: 7762715 
  4. Cohen D, Bassal R, Goren S, Rouach T, Taran D, Schemberg B, et al. Recent trends in the epidemiology of shigellosis in Israel. Epidemiol Infect. 2014;142(12):2583-94.  https://doi.org/10.1017/S0950268814000260  PMID: 24559503 
  5. Cohen D, Korin H, Bassal R, Perry Markovich M, Sivan Y, Goren S, et al. Burden and risk factors of Shigella sonnei shigellosis among children aged 0-59 months in hyperendemic communities in Israel. Int J Infect Dis. 2019;82:117-23.  https://doi.org/10.1016/j.ijid.2019.02.031  PMID: 30831222 
  6. Kotloff KL, Riddle MS, Platts-Mills JA, Pavlinac P, Zaidi AKM. Shigellosis. Lancet. 2018;391(10122):801-12.  https://doi.org/10.1016/S0140-6736(17)33296-8  PMID: 29254859 
  7. Charles H, Prochazka M, Thorley K, Crewdson A, Greig DR, Jenkins C, et al. Outbreak of sexually transmitted, extensively drug-resistant Shigella sonnei in the UK, 2021-22: a descriptive epidemiological study. Lancet Infect Dis. 2022;22(10):1503-10.  https://doi.org/10.1016/S1473-3099(22)00370-X  PMID: 35809593 
  8. Baker S, Scott TA. Antimicrobial-resistant Shigella: where do we go next? Nat Rev Microbiol. 2023;21(7):409-10.  https://doi.org/10.1038/s41579-023-00906-1  PMID: 37188805 
  9. World Health Organization (WHO). Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae type 1. Geneva: WHO; 1 Jan 2005. Available from: https://www.who.int/publications/i/item/9241592330
  10. Lefèvre S, Njamkepo E, Feldman S, Ruckly C, Carle I, Lejay-Collin M, et al. Rapid emergence of extensively drug-resistant Shigella sonnei in France. Nat Commun. 2023;14(1):462.  https://doi.org/10.1038/s41467-023-36222-8  PMID: 36709320 
  11. World Bank Group. High income. Washington DC: World Bank Group. [Accessed: 31 May 2024]. Available from: https://data.worldbank.org/country/XD
  12. Central Bureau of Statistics (CBS). Characterization and classification of geographical units by the socio-economic level of the population 2017. Jerusalem: CBS; Aug 2021. Available from: https://www.cbs.gov.il/he/publications/DocLib/2021/socio_eco17_1832/e_print.pdf
  13. Clinical and Laboratory Standards (CLSI). M100–Performance standards for antimicrobial susceptibility testing, 31st edition. Malvern: CLSI; 29 Mar 2021.Available from: https://clsi.org/about/press-releases/clsi-publishes-m100-performance-standards-for-antimicrobial-susceptibility-testing-31st-edition/
  14. Abramson JH. WINPEPI updated: computer programs for epidemiologists, and their teaching potential. Epidemiol Perspect Innov. 2011;8(1):1.  https://doi.org/10.1186/1742-5573-8-1  PMID: 21288353 
  15. Centers for Disease Control and Prevention (CDC). National Enteric Disease Surveillance: Shigella Annual Report, 2016. Atlanta: CDC; Mar 2018. Available from: https://www.cdc.gov/nationalsurveillance/pdfs/LEDS-Shig-2016-REPORT-508.pdf
  16. European Centre for Disease Prevention and Control (ECDC). Shigellosis - Annual Epidemiological Report for 2019. Stockholm: ECDC; 19 Dec 2022. Available from: https://www.ecdc.europa.eu/en/publications-data/shigellosis-annual-epidemiological-report-2019
  17. Sagas D, Adler A, Kasher C, Khamaysi K, Strauss M, Chazan B. The effect of the transition to molecular diagnosis on the epidemiology and the clinical characteristics of bacterial gastroenteritis in Northern Israel. Infect Dis (Lond). 2024;56(2):157-63.
  18. Liu J, Garcia Bardales PF, Islam K, Jarju S, Juma J, Mhango C, et al. Shigella detection and molecular serotyping with a customized TaqMan Array Card in the Enterics for Global Health (EFGH): Shigella surveillance study. Open Forum Infect Dis. 2024;11(Suppl 1):S34-40.  https://doi.org/10.1093/ofid/ofad574  PMID: 38532960 
  19. Clarfield AM, Manor O, Nun GB, Shvarts S, Azzam ZS, Afek A, et al. Health and health care in Israel: an introduction. Lancet. 2017;389(10088):2503-13.  https://doi.org/10.1016/S0140-6736(17)30636-0  PMID: 28495109 
  20. Adamker G, Holzer T, Karakis I, Amitay M, Anis E, Singer SR, et al. Prediction of Shigellosis outcomes in Israel using machine learning classifiers. Epidemiol Infect. 2018;146(11):1445-51.  https://doi.org/10.1017/S0950268818001498  PMID: 29880081 
  21. Bassal R, Lerner L, Valinsky L, Agmon V, Peled N, Block C, et al. Trends in the epidemiology of campylobacteriosis in Israel (1999-2012). Foodborne Pathog Dis. 2016;13(8):448-55.  https://doi.org/10.1089/fpd.2015.2096  PMID: 27203409 
  22. Peer V, Schwartz N, Green MS. Sex differences in shigellosis incidence rates: analysis of national data from nine countries using meta-analytic method. Eur J Public Health. 2020;30(5):974-81.  https://doi.org/10.1093/eurpub/ckaa087  PMID: 32535632 
  23. Thompson CN, Duy PT, Baker S. The rising dominance of Shigella sonnei: an intercontinental shift in the etiology of bacillary dysentery. PLoS Negl Trop Dis. 2015;9(6):e0003708.  https://doi.org/10.1371/journal.pntd.0003708  PMID: 26068698 
  24. Matanza XM, Clements A. Pathogenicity and virulence of Shigella sonnei: A highly drug-resistant pathogen of increasing prevalence. Virulence. 2023;14(1):2280838.  https://doi.org/10.1080/21505594.2023.2280838  PMID: 37994877 
  25. Livio S, Strockbine NA, Panchalingam S, Tennant SM, Barry EM, Marohn ME, et al. Shigella isolates from the global enteric multicenter study inform vaccine development. Clin Infect Dis. 2014;59(7):933-41.  https://doi.org/10.1093/cid/ciu468  PMID: 24958238 
  26. MacLennan CA, Grow S, Ma LF, Steele AD. The Shigella vaccines pipeline. Vaccines (Basel). 2022;10(9):1376.  https://doi.org/10.3390/vaccines10091376  PMID: 36146457 
  27. The Israel Democracy Institute (IDI). Statistical Report on Ultra-Orthodox Society in Israel. Jerusalem: IDI; 1 Jan 2021. Available from: https://en.idi.org.il/haredi/2020/?chapter=34272
  28. Cohen D, Meron-Sudai S, Bialik A, Asato V, Goren S, Ariel-Cohen O, et al. Serum IgG antibodies to Shigella lipopolysaccharide antigens - a correlate of protection against shigellosis. Hum Vaccin Immunother. 2019;15(6):1401-8.  https://doi.org/10.1080/21645515.2019.1606971  PMID: 31070988 
  29. Behar A, Baker KS, Bassal R, Ezernitchi A, Valinsky L, Thomson NR, et al. Microevolution and patterns of transmission of Shigella sonnei within cyclic outbreaks shigellosis, Israel. Emerg Infect Dis. 2018;24(7):1335-9.  https://doi.org/10.3201/eid2407.171313  PMID: 29912703 
  30. Bassal R, Keinan-Boker L, Cohen D. A significant decrease in the incidence of shigellosis in Israel during COVID-19 pandemic. Int J Environ Res Public Health. 2021;18(6):3070.  https://doi.org/10.3390/ijerph18063070  PMID: 33809746 
Twenty-five years of sentinel laboratory-based surveillance of shigellosis in a high-income country endemic for the disease, Israel, 1998 to 2022
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Dani+Cohen&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Cohen Dani</a>, <a href="/search?value1=Orit+Treygerman&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Treygerman Orit</a>, <a href="/search?value1=Shifra+Ken-Dror&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ken-Dror Shifra</a>, <a href="/search?value1=Orli+Sagi&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Sagi Orli</a>, <a href="/search?value1=Merav+Strauss&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Strauss Merav</a>, <a href="/search?value1=Miriam+Parizade&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Parizade Miriam</a>, <a href="/search?value1=Sophy+Goren&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Goren Sophy</a>, <a href="/search?value1=Anal%C3%ADa+V+Ezernitchi&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ezernitchi Analía V</a>, <a href="/search?value1=Assaf+Rokney&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Rokney Assaf</a>, <a href="/search?value1=Lital+Keinan-Boker&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Keinan-Boker Lital</a>, <a href="/search?value1=Ravit+Bassal&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bassal Ravit</a></span>. Twenty-five years of sentinel laboratory-based surveillance of shigellosis in a high-income country endemic for the disease, Israel, 1998 to 2022. <a href="/content/ecdc">Euro Surveill.</a> 2024;29(31):pii=2400022. <a href="https://doi.org/10.2807/1560-7917.ES.2024.29.31.2400022" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2024.29.31.2400022</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 03 Jan 2024;&nbsp;&nbsp; <span class="generated">Accepted</span>: 16 May 2024 </span> </p>
/content/10.2807/1560-7917.ES.2024.29.31.2400022
/content/10.2807/1560-7917.ES.2024.29.31.2400022
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error